MetaCap

AbbVie (ABBV) vs Vertex Pharmaceuticals (VRTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AbbVie (ABBV) has outperformed Vertex Pharmaceuticals (VRTX) over the past year, gaining 21.1% versus a gain of 20.7%. Over five years, VRTX leads with a +180.5% price change compared with +145.6% for ABBV. AbbVie is the larger company by market cap ($505.89 billion vs $130.58 billion), about 3.9 times the size, while Vertex Pharmaceuticals is growing revenue faster (+8.9% vs +8.6%).

On valuation, AbbVie trades at a lower forward P/E (17.6x vs 25.9x for Vertex Pharmaceuticals). AbbVie pays a dividend yielding 2.42%, while Vertex Pharmaceuticals does not currently pay one. Vertex Pharmaceuticals converts more of its revenue into profit, with a net margin of 32.9% versus 6.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABBV+21.13%VRTX+20.68%
+33%+7%-19%
Nov 21, 20251 yearNov 20, 2026
ABBV+146.21%VRTX+181.62%
+216%+103%-10%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABBV versus VRTX key metrics
MetricABBVVRTX
Share price$286.20$515.02
Market cap$505.89B$130.58B
1-day change+0.94%-1.08%
YTD return+25.26%+13.60%
1-year return+21.13%+20.68%
5-year return+145.64%+180.53%
P/E ratio (TTM)49.1833.14
Forward P/E17.6525.86
EPS (TTM)$5.82$15.54
Dividend yield2.42%0.00%
Annual dividend$6.92$0.00
Revenue (latest FY)$61.16B$12.00B
Revenue growth (YoY)+8.57%+8.90%
Net income (latest FY)$4.23B$3.95B
Gross margin70.24%86.24%
Operating margin24.65%34.77%
Net margin6.91%32.94%
52-week high$302.93$568.67
52-week low$190.75$412.27
Distance from 52-week high-5.52%-9.43%
Analyst consensusbuybuy
Avg. price target upside+9.76%+15.60%
Average volume4.84M1.25M
Shares outstanding1.77B253.54M
Employees57,0006,400
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AbbVie is about 3.9 times larger than Vertex Pharmaceuticals by market value ($505.89B vs $130.58B).
  • AbbVie trades at a higher earnings multiple (49.2x vs 33.1x trailing P/E).
  • AbbVie offers a meaningfully higher dividend yield (2.42% vs 0.00%).
  • Vertex Pharmaceuticals is more profitable, keeping 32.9 cents of every revenue dollar as net income versus 6.9 cents for AbbVie.

About AbbVie

ABBV stock →

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 57,000 employees

About Vertex Pharmaceuticals

VRTX stock →

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.

Health Care · Biotechnology: Pharmaceutical Preparations · 6,400 employees

ABBV vs VRTX FAQ

Which is bigger, AbbVie or Vertex Pharmaceuticals?

AbbVie (ABBV) is larger, with a market capitalization of $505.89B compared with $130.58B for Vertex Pharmaceuticals (VRTX).

Which stock has performed better over the past year, ABBV or VRTX?

ABBV returned +21.13% over the past 12 months, compared with +20.68% for VRTX (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, ABBV or VRTX?

VRTX has the lower trailing P/E at 33.1, versus 49.2 for ABBV. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, AbbVie or Vertex Pharmaceuticals?

AbbVie pays a dividend yielding 2.42%, while Vertex Pharmaceuticals does not currently pay a regular dividend.

Are AbbVie and Vertex Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons